We use cookies to improve site performance and enhance your user experience. If you'd like to disable
cookies on this device, please see our
cookie management page.
If you close this message or continue to use this site, you consent
to our use of cookies on this devise in accordance with our
cookie policy, unless you disable
them.
These results recorded a lull in operations for cough medicines developer Vectura, as management waits for news from various regulatory filings and for its partners to complete clinical trials. But, with a hefty cash pile, the group can afford to wait.
subscriber-only content
visible-status-Subscription-Only story-url-Vectura results 2011.xml
